Leaving INTR@PID website

You are leaving INTR@PID Clinical Trials page. This link will take you to a website where our Terms of Use do not apply. Merck KGaA, Darmstadt, Germany has no control over the contents and policies of these sites or resources, and accepts no responsibility for your use of them.

Please Confirm

This website is an information resource intended only for Healthcare Professionals who are interested in information on Clinical Research and clinical trials conducted under a partnership between EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, and GSK.

By clicking "I am a healthcare professional" you are declaring and confirming that you are a Healthcare Professional inside the U.S., and have read and understood this disclaimer.

BREAST CANCER

Investigational clinical trial in breast cancer


BREAST 020

METASTATIC

PHASE 2

MONOTHERAPY


INTR@PID BREAST 020 (NCT04489940) is a clinical trial assessing the efficacy and safety of bintrafusp alfa for the treatment of metastatic triple-negative breast cancer that has high expression of HMGA21

 Status:

Now Enrolling


What is breast cancer?


Breast cancer is one of the most common cancers, with approximately 2.3 million people diagnosed worldwide in 20202-4

Most breast cancers start in the ducts or lobes and are classified as carcinomas.5-7 Breast cancers can be grouped based on the presence or absence of certain biological molecules in the cells of the body, called biomarkers.5,8 Normal breast cells have biomarkers that may be found at higher or lower levels in breast cancer5

There are 3 main biomarkers in breast cancer5:

  • Estrogen receptor (ER): a type of protein called a receptor that binds the hormone estrogen.9 Breast cancers that do not have this biomarker are called ER-negative, and breast cancers that have this biomarker are called ER-positive5
  • Progesterone receptor (PR): a receptor that binds the hormone progesterone.10 Breast cancers that do not have this biomarker are called PR-negative, and breast cancers that have this biomarker are called PR-positive5
  • Human epidermal growth factor receptor 2 (HER2): a receptor that is involved in cell growth.5 Breast cancers that have a normal level of this biomarker are called HER2-negative, and breast cancers that have a higher level are called HER2-positive5

Triple-negative breast cancer is a type of cancer that is ER-negative, PR-negative, and HER2-negative5

The breasts and cancer


  1. ClinicalTrials.gov. Bintrafusp alfa in high mobility group AT-hook 2 (HMGA2) expressing triple negative breast cancer. Accessed March 8, 2021. https://clinicaltrials.gov/ct2/show/NCT04489940.
  2. Ferlay J, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Accessed 14 May 2021. https://gco.iarc.fr/today.
  3. Giordano SH, et al. Cancer. 2004;101:51-7.
  4. Cardoso F, et al. Ann Oncol. 2018;29:405-17.
  5. National Cancer Institute. Accessed March 8, 2021. Breast cancer treatment (adult) (PDQ)–patient version. https://www.cancer.gov/types/breast/patient/breast-treatment-pdq.
  6. American Cancer Society. What is breast cancer? Accessed March 8, 2021. https://www.cancer.org/cancer/breast-cancer/about/what-is-breast-cancer.html. 
  7. American Cancer Society. What is breast cancer in men? Accessed March 8, 2021. https://www.cancer.org/cancer/breast-cancer-inmen/about/what-is-breast-cancer-in-men.html. 
  8. National Cancer Institute. NCI dictionary of cancer terms. Accessed March 8, 2021. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/biomarker.
  9. National Cancer Institute. NCI dictionary of cancer terms. Accessed March 8, 2021. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/estrogen-receptor.
  10. National Cancer Institute. NCI dictionary of cancer terms. Accessed March 8, 2021. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/progesterone-receptor.

 

 

 

Explore the Knowledge Base